Compare DexCom, Inc. (DXCM) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Raymond James Financial, Inc. — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Raymond James Financial, Inc. trades at $158.28 (market cap $30.51B). The key difference: DexCom, Inc. and Raymond James Financial, Inc. are close in size by market cap, and Raymond James Financial, Inc. pays a 1.36% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Raymond James Financial, Inc. for 75 Days on average.
| DXCM | RJF | |
|---|---|---|
Market Cap | $31.86B | $30.51B |
Volume | 3,607,070 | 1,206,253 |
Sector | Health | Financials |
52-Week High | $92.34 | $181.18 |
52-Week Low | $54.84 | $140.89 |
Typical Hold Time | 62 Days | 75 Days |
Enterprise Value | $31.32B | $24.37B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Raymond James Financial (RJF) trades at $158.60, up 0.83% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 15.37% net margins and 18.48% ROE. Recent Q3 2026 results showed record revenues of $3.93 billion, beating expectations. The company continues dividend payments with a $0.54 quarterly payout declared for October 2026.
RJF presents a mixed outlook with strong fundamental performance offset by technical weakness. The 16% upside to consensus price target of $184.00 offers potential, but investors face headwinds from rising expenses and market volatility. The absence of sell ratings and consistent institutional interest supports the investment case, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
